TY - JOUR
T1 - Prognostic impact of sarcopenia in children with cancer: a focus on the psoas muscle area (PMA) imaging in the clinical practice
AU - Triarico, Silvia
AU - Rinninella, Emanuele
AU - Mele, Maria Cristina
AU - Cintoni, Marco
AU - Attinà, Giorgio
AU - Ruggiero, Antonio
PY - 2021
Y1 - 2021
N2 - Skeletal muscle plays a crucial part in the metabolic and inflammatory response. “Sarcopenia”, defined as a pathological condition of reduced strength, quantity and quality of skeletal muscle mass, may often develop in the young age as the secondary consequence of a systemic inflammatory illness, like cancer. In children with cancer, sarcopenia is a common finding, playing a negative role in their prognosis. However, its prevalence in clinical practice is underestimated. Moreover, several pre- and post-natal factors may influence skeletal muscle development in childhood, making the issue more complex. Given the frequent use of radiological imaging in clinical practice, prompt analysis of body composition is feasible and able to detect the presence of reduced fat-free mass (FFM) among pediatric patients with cancer. We discuss the recent advances in the study of body composition in children with cancer, dissecting the role of the psoas muscle area (PMA) measure, obtained from computerized tomography (CT) or magnetic resonance images (MRI) as a marker of sarcopenia in this setting. Since age and sex-specific percentile curves for PMA and a PMA z-scores calculator are available online, such a tool may be useful to simply detect and treat sarcopenia and its consequences in childhood cancer.
AB - Skeletal muscle plays a crucial part in the metabolic and inflammatory response. “Sarcopenia”, defined as a pathological condition of reduced strength, quantity and quality of skeletal muscle mass, may often develop in the young age as the secondary consequence of a systemic inflammatory illness, like cancer. In children with cancer, sarcopenia is a common finding, playing a negative role in their prognosis. However, its prevalence in clinical practice is underestimated. Moreover, several pre- and post-natal factors may influence skeletal muscle development in childhood, making the issue more complex. Given the frequent use of radiological imaging in clinical practice, prompt analysis of body composition is feasible and able to detect the presence of reduced fat-free mass (FFM) among pediatric patients with cancer. We discuss the recent advances in the study of body composition in children with cancer, dissecting the role of the psoas muscle area (PMA) measure, obtained from computerized tomography (CT) or magnetic resonance images (MRI) as a marker of sarcopenia in this setting. Since age and sex-specific percentile curves for PMA and a PMA z-scores calculator are available online, such a tool may be useful to simply detect and treat sarcopenia and its consequences in childhood cancer.
KW - pediatric oncology
KW - psoas muscle
KW - sarcopenia
KW - pediatric oncology
KW - psoas muscle
KW - sarcopenia
UR - http://hdl.handle.net/10807/191507
U2 - 10.1038/s41430-021-01016-y
DO - 10.1038/s41430-021-01016-y
M3 - Article
SN - 0954-3007
VL - 2021
SP - 1
EP - 6
JO - European Journal of Clinical Nutrition
JF - European Journal of Clinical Nutrition
ER -